Medical Therapy of Claudication and Lower Extremity Arterial Disease

  • Dennis G. Caralis
Part of the Clinical Hypertension and Vascular Diseases book series (CHVD)


The new millennium found lower extremity arterial disease (LEAD) and intermittent claudication in particular, pharmacotherapeutically orphan. Pharmacologically, intermittent claudication has been an orphan since it was first described many decades ago. Intermittent claudication, the cardinal symptom of LEAD occurs in 35 to 50% of patients with known LEAD documented by noninvasive diagnostic methods (1). The development of effective pharmacotherapy for treating claudication has lagged behind that for treating angina pectoris and other manifestations of myocardial ischemia.


Peripheral Arterial Disease Antiplatelet Therapy Intermittent Claudication Heart Outcome Prevention Evaluation Therapeutic Angiogenesis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. J Vase Surg 2000;31:S1–S296.CrossRefGoogle Scholar
  2. 2.
    Cameron HA, Walter PC, Ramsay LE. Drug treatment of intermittent claudication: A critical analysis of the methods and findings of published clinical trials. 1965–1985. Br J Clin Pharmacol 1998;26:569–576.Google Scholar
  3. 3.
    Hirsch AT. Claudication as an “orphan disease” rationale and goals of drug therapy for peripheral arterial disease. Vase Med 1996;1:37–42.Google Scholar
  4. 4.
    McDermott MM, Mehta S, Liuk, et al. Legs symptoms, the ankle-brachial index, and walking ability in patients with peripheral arterial disease. J Gen Internal Med 1999;14:173–181.CrossRefGoogle Scholar
  5. 5.
    Aangelkort B, Spurk P, Habbaba A, et al. Blood flow properties and walking performance in chronic arterial occlusive disease. Angiology 1985;36:285–292.Google Scholar
  6. 6.
    Hansen Pr, Holm AM, Qi JH et al. Pentoxifylline inhibits neointimal formation and stimulates constrictive vascular remodeling after arterial injury. J Cardiovascular Pharmacology 199;34:683–689.Google Scholar
  7. 7.
    Chen YM, Wu KD, Tsai TJ, et al. Pentoxifylline inhibits PDGF-induced proliteration of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. JMol Cell Cardiol 1999;31:773–783.CrossRefGoogle Scholar
  8. 8.
    Peter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66–72.CrossRefGoogle Scholar
  9. 9.
    Lindgarde F, Labs KH, Rosher M. The pentoxifylline experience: Exercise testing reconsidered. Vase Med 1996;1:145–154.Google Scholar
  10. 10.
    Linderde F, Jelnesr, Bjorkmen H. et al. Conservative drug treatment in patients with moderatley severe chromic occlusive peripheral arterial disease. Scandinavion Study Group. Circulation 1989;80:1549–1556.Google Scholar
  11. 11.
    Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 1996;155:1053–1059.Google Scholar
  12. 12.
    Girolami B, Bernardi E, Prins MH et al. Treatment of intermittent claudication with physical training, smoking sessation, with pentoxifylline or nafronyl: a meta-analysis. Arch lntMed 1999;159:337–345.Google Scholar
  13. 13.
    Radock K, Wyderski RJ. Conservative management of the intermittent claudication. Ann Int Med 1990;113:135–146.Google Scholar
  14. 14.
    Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996;94:3026–3049.PubMedGoogle Scholar
  15. 15.
    Cameron HA, Walker PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials 1965–1985. BrJClin Pharmacol 1988;26:569–576.Google Scholar
  16. 16.
    Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Int Med 1990;113:135–146.PubMedGoogle Scholar
  17. 17.
    Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, Forbes WP, and Strandness DE. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523–530.PubMedCrossRefGoogle Scholar
  18. 18.
    Kamiya T, Sakaguchi S. Hemodynamic effects of theantithrombotic drug cilostazol in chronic arterial occlusion in the extremities. Arzneimitte Eforschung 1985;35:1201–1203.Google Scholar
  19. 19.
    Feldman AM, McNamara DM. Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease. Clin Cardiol 2002;25:256–262.PubMedCrossRefGoogle Scholar
  20. 20.
    Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication casued by peripheral vascular disease. J Vase Surg 1998;27:267–274.CrossRefGoogle Scholar
  21. 21.
    Beebe HJ, Dawson DL, Cutler BJ. Et al. A new pharmacologic treatment for intermittent claudication; results of a randomized multicenter trial. Arch Int Med 1999;159:2041–2050.CrossRefGoogle Scholar
  22. 22.
    Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Eng J Med 2001;344(21):1608–21.CrossRefGoogle Scholar
  23. 23.
    Physicians’ Desk Reference. Pletal (cilostazol), 58th ed. 2004; pp. 2500–2503.Google Scholar
  24. 24.
    Dawson DL, DeMaioribus CA, Higino RT, et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 1999;178:141–146.PubMedCrossRefGoogle Scholar
  25. 25.
    Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double blind trial. Circulation 1998;98:678–686.PubMedGoogle Scholar
  26. 26.
    Elam MD, Heckman J, Crouse JR, et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscl Thromb Vase Biol 1998;18:1942–1947.Google Scholar
  27. 27.
    Bramer SL, Forbes WP. Effect of hepatic impairment on the pharmacokeinetics of a single dose of cilostazol. Clin Pharmacokin 1999;37:25–32.CrossRefGoogle Scholar
  28. 28.
    Mallikaarjun S, Forbes WP, Bramer SL. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. Clin Pharmacokin 1999;37:33–40.CrossRefGoogle Scholar
  29. 29.
    Packer M, Carver JR, Rodeneffer RJ, et al. Effect of oral milrinone on mortality in severe congestive heart failure. N Eng J Med 1991;325:1468–1475.CrossRefGoogle Scholar
  30. 30.
    Sorkin EM, Markham A. Cilostazol: new drug profile. Drugs Aging 1999;14:63–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Hiatt WR, Authony Koda 1. Benefit of NM-702, a phosphodiesterase inhibitor in the treatment of claudication presented during the. Circulation 2003; abstract 2676.Google Scholar
  32. 32.
    Ferrar N, Houck K, Jakeman L, Louig DW. Molecular and biological properties of the vascular endolethial growth factor family of proteins. Endocrinol Rev 1992;13:18–32.CrossRefGoogle Scholar
  33. 33.
    Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angio-gensis. Am JPathol 1995;146:1029–1039.Google Scholar
  34. 34.
    Takeshita S, Zheng LP, Ashara T, et al. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments collateral vessel formation in a rabbit ischemic hind limb. J Clin Invest 1994;93:662–670.PubMedGoogle Scholar
  35. 35.
    Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996;271:603–606.PubMedGoogle Scholar
  36. 36.
    Pul A, Sniderman AD, Brassard R, Lochapelle KJ, Graham AM, Lisbona R. Enhanced revascularization of the ischemic limb by means of angiogenic therapy. Circulation 1993;88:208–214.Google Scholar
  37. 37.
    Levy PL, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996;271:2746–2753.PubMedCrossRefGoogle Scholar
  38. 38.
    Brogi E, Schatteman G, Wu T, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor recptor expression. J Clin Invest 1996;97:469–476.PubMedCrossRefGoogle Scholar
  39. 39.
    Waltenberger J, Mayr V, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996;94:1647–1654.PubMedGoogle Scholar
  40. 40.
    Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor. J Vase Surg 1992;16:181–191.CrossRefGoogle Scholar
  41. 41.
    Maisonpierre PC, Suric, Jones PF, Bortunkova S. Angioprotein-2, a natural antagonist for Tie2 that disrupts in vio angiogenesis. Science 1997;277:55–60.PubMedCrossRefGoogle Scholar
  42. 42.
    Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389–395.PubMedCrossRefGoogle Scholar
  43. 43.
    Lederman RJ, Mendel John FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication. (the TRAFFIC Study): a randomized trial. Lancet 2002;359:2053–2058.PubMedCrossRefGoogle Scholar
  44. 44.
    Baumgartner I, Pieczek A, Manor O, et al. Consecutive expression of ph VEGF 165 after intra-muscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114–1123.PubMedGoogle Scholar
  45. 45.
    Iba O, Matsuraba H, Takenobu I, Fujiyamas, Masaki H, Okigaki M, I Wasaka T,. Implantation of platelets induces collateral vessel formation in a VEGF-dependent manner-new cell source for therapeutic angiogenesis. Circulation 2003; Abstract 511.Google Scholar
  46. 46.
    Jonasou T, Bergstrom R. Cessation of smoking in patients with intermittent claudicatio. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Medical Scandinavica 1987;221:253–260.Google Scholar
  47. 47.
    Lassila R, Lepentalo M. Cigarette smoking and the outcome offer lower limb arterial surgery. Acta Chirourgika Scandinavica 1998;154:635–640.Google Scholar
  48. 48.
    Quick CR, Cotton IT. The measured effect of stopping smoking on intermittent claudication. BrJSurg 1992; S24–S26.Google Scholar
  49. 49.
    Ingolfsson LO, Sigurdsson G, Sigvaldoson H, et al. A marked decline in the prevalence and incidence of intermittent claudication in Icelandic Men. 1968–1986: A strong relationship to smoking and serum cholesterol. The Reykjavik Study. J Clin Epidemiol 1994;47:1237–1243.PubMedCrossRefGoogle Scholar
  50. 50.
    Faulkner KW, House AK, Casteldan WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Australia 1983;1:217–219.PubMedGoogle Scholar
  51. 51.
    Hurt RD, Sacks DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Eng J Med 1997;337:1195–1202.CrossRefGoogle Scholar
  52. 52.
    Caralis DG, Deligonul U, Kern MJ, Cohen JD. Smoking is a Risk Factor for Coronary Spasm in Young Women. Circulation 1992;85:905–909.PubMedGoogle Scholar
  53. 53.
    Foukes FG, Housley E, riemersma RA, et al. Smoking lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992;135:331–341.Google Scholar
  54. 54.
    Murabito JM, D’Agostino RB, Siblershatz H, et al. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96:44–49.PubMedGoogle Scholar
  55. 55.
    Chobanian AV, Bakris GL, Black HR, Cushman W C, Green LA, Izzo Jr. JL, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 Report. JAMA 2003;289:2560–2572.PubMedCrossRefGoogle Scholar
  56. 56.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes melitus. NEng JMed 1993;329:977–986.CrossRefGoogle Scholar
  57. 57.
    Effect of intensive diabetes management of macrovascular events and risk factors in the Diabetes Control and Complications trial. Am J Cardiol 1995;75:894–903.Google Scholar
  58. 58.
    United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes erratum appears in Lancet. Lancet 1999;354:602.Google Scholar
  59. 59.
    Orchard TJ, Strandness DE, Jr. Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American Heart Association and the American Diabetes Association 18–20 September 1992. New Orleans, Louisiana. Diabetes Care 1993;16:1199–1209.PubMedGoogle Scholar
  60. 60.
    Kannel WB, Skinner JJ, Jr., Schwartz MJ, et al. Intermittent claudication. incidence in the Farmingham Study. Circulation 1970;41:875–883.PubMedGoogle Scholar
  61. 61.
    Alderman MH, Madhavan S, Ool WL, et al. Association of the Renin-Sodium profile with the risk of myocardial infarction in patients with hypertension. N Eng JMed 1991;324:1098–104.CrossRefGoogle Scholar
  62. 62.
    Yusuf S, Sleight P. Pogue J, et al. Effects of an angiotensis-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Eng J Med 2000;342:145–153.CrossRefGoogle Scholar
  63. 63.
    Aconow WS, Nayuk D, Woodworm S, and Ahn C. Effects of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003;92:711–772.CrossRefGoogle Scholar
  64. 64.
    Hirsch AT, Criqui MN, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness and treatment in primary care. JAMA 2001;286:1317–1324.PubMedCrossRefGoogle Scholar
  65. 65.
    Hirsch AT, Halverson SL, Treat-Jacobson D, et al. The Minnessota Regional Perpheral Arterial Disease Screening Program; toward a definition of community standards of care. Vase Med 2001;6:87–96.Google Scholar
  66. 66.
    Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;324:71–86.CrossRefGoogle Scholar
  67. 67.
    Goldhaber SZ, Manson JE, Stampler MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study. Lancet 1992;340:143–145.PubMedCrossRefGoogle Scholar
  68. 68.
    CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329–1339.CrossRefGoogle Scholar
  69. 69.
    Aronow WS, Nayak D, Woodworth S, Cahn. Effect of simvastatin versus placebo on exercise time until onset of intermittent claudication. Circulation 2003;108:2557.Google Scholar
  70. 70.
    Harold Bays. Ezetimibe. Expert opinion. Investigate Drugs 2002;11:1587–1601.CrossRefGoogle Scholar
  71. 71.
    Nissen SE, Tuzcu EM, Schoenhagen PS, for the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA 2004;291:107–108.CrossRefGoogle Scholar
  72. 72.
    Topol EJ. Intensive statin therapy-A sea change in cardiovascular prevention. N EngJMed 2004;350:15. Scholar
  73. 73.
    Markwood TT, Kent SM, Coyle LC, Flaherty PJ, O’Malley PG, Taylor AJ. Design and rationale of the ARBITER Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol) a randomized trial comparing the effects of atorvastatin on carotid artery intima-medial thickness. Am Heart J 2001;141:342–347.PubMedCrossRefGoogle Scholar
  74. 74.
    Kent SM, Coyle LC, Flaherty PJ, Markwood TT, Taylor AJ. Marked low density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest teduction in carotid atherosclerosis. Clin Cardiol 2004;27:17–21.PubMedCrossRefGoogle Scholar
  75. 75.
    Barter PJ, Brewer HB Jr, Chapman MJ, et al. Cholesteryl ester transfer protein: a navel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vase Biol 2003;23:160–167.CrossRefGoogle Scholar
  76. 76.
    Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2487–2497.CrossRefGoogle Scholar
  77. 77.
    Brown WV, Dujovnce CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipi-demia. Arteriosclerosis 1986;6:670–678.PubMedGoogle Scholar
  78. 78.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll of Cardiol 1986;8:1245–1255.CrossRefGoogle Scholar
  79. 79.
    Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233–3240.PubMedCrossRefGoogle Scholar
  80. 80.
    Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013–3017.PubMedCrossRefGoogle Scholar
  81. 81.
    Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across does (STELLAR Trial). Am J Cardiol 2003;92:152–160.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Dennis G. Caralis
    • 1
  1. 1.Division of Cardiology, Department of MedicineRush University Medical CenterChicago

Personalised recommendations